Mechanistic and therapeutic perspectives for cardiac arrhythmias: beyond ion channels

Yufei Wu1,2,3, Jun Li1,2,3, Liang Xu1,2

  • 1Key Laboratory of Arrhythmias of the Ministry of Education of China, Tongji University, Shanghai, 200092, China.

Insights

Cardiac arrhythmias, a leading cause of death, involve more than just ion channel defects. This review explores new cellular mechanisms and discusses developing safer, more effective antiarrhythmic treatments.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cellular Biology

Background:

  • Cardiac arrhythmias are a major global health concern and a leading cause of mortality worldwide.
  • While ion channel disorders are recognized causes of arrhythmias, they do not explain all cases.
  • Current antiarrhythmic drugs have limited efficacy and can cause proarrhythmic effects.

Purpose of the Study:

  • To review novel cellular mechanisms underlying cardiac arrhythmias.
  • To focus on the role of subcellular organelle dysfunction and intracellular transport in arrhythmia development.
  • To discuss potential strategies and challenges for developing new antiarrhythmic therapies.

Main Methods:

  • Literature review of foundational and recent studies on cardiac arrhythmias.
  • Analysis of cellular and molecular mechanisms contributing to arrhythmia.
  • Discussion of therapeutic targets related to organelle function and intracellular logistics.

Main Results:

  • Identified dysfunction of subcellular organelles (e.g., sarcoplasmic reticulum, mitochondria) as key contributors to arrhythmias.
  • Highlighted the importance of intracellular logistics, including protein trafficking and calcium handling, in maintaining cardiac rhythm.
  • Emphasized that non-ion channel defects are significant factors in arrhythmia pathogenesis.

Conclusions:

  • Cardiac arrhythmias result from complex cellular dysfunctions beyond simple ion channel mutations.
  • Targeting subcellular organelles and intracellular transport pathways offers promising avenues for novel antiarrhythmic drug development.
  • Future research should focus on these novel mechanisms to create safer and more effective treatments for arrhythmias.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.5K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
547
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Electrophysiology of Normal Cardiac Rhythm01:19

Electrophysiology of Normal Cardiac Rhythm

The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
10.0K